| Title: |
Breast Cancer Survival Outcomes and Tumor-Associated Macrophage Markers: A Systematic Review and Meta-Analysis. |
| Authors: |
Allison, Eleanor, Edirimanne, Senarath, Matthews, Jim, Fuller, Stephen J. |
| Source: |
Oncology & Therapy; Mar2023, Vol. 11 Issue 1, p27-48, 22p |
| Subject Terms: |
BREAST cancer prognosis, BIOMARKERS, META-analysis, CONFIDENCE intervals, MEDICAL information storage & retrieval systems, SYSTEMATIC reviews, MACROPHAGES, CANCER patients, TREATMENT effectiveness, RESEARCH funding, PROGRESSION-free survival, MEDLINE, DATA analysis software, OVERALL survival, EVALUATION |
| Abstract: |
Introduction: Tumor-associated macrophages (TAMs) in breast cancer are associated with a poor prognosis. Early studies of TAMs were largely limited to the pan-macrophage marker CD68, however, more recently, an increasing number of studies have used CD163, a marker expressed by alternatively activated M2 macrophages and TAM subsets. We hypothesized that CD163-positive (CD163+) TAMs would be a better predictor of survival outcomes in breast cancer compared to CD68+ TAMs. Methods: We performed a systematic literature search of trials (from 1900 to August 2020) reporting overall survival (OS) or progression-free survival (PFS), breast cancer-specific survival (BCSS), TAM phenotype, and density. Thirty-two studies with 8446 patients were included. Meta-analyses were carried out on hazard ratios (HRs) for survival outcomes of breast cancer patients with a high density of TAMs (CD68+ and/or CD163+) compared to a low density of TAMs. Results: A high density of TAMs (CD68+ and/or CD163+) was associated with decreased OS (HR 1.69, 95% CI 1.37–2.07) and reduced PFS (HR 1.64; 95% CI 1.35–1.99). Subgrouping by CD marker type showed a lower OS for high density of CD163+ TAMs (HR 2.24; 95% CI 1.71–2.92) compared to a high density of CD68+ TAMs (HR 1.5; 95% CI 1.12–2). A high density of TAMs (CD68+ and/or CD163+) in triple-negative breast cancer (TNBC) cases was associated with lower OS (HR 2.81, 95% CI 1.35–5.84). Conclusion: Compared to CD68+ TAMs, a high density of CD163+ TAMs that express a similar phenotype to M2 macrophages are a better predictor of poor survival outcomes in breast cancer. [ABSTRACT FROM AUTHOR] |
|
Copyright of Oncology & Therapy is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
